NMPA approves by BYVASDA (Bevadan antisimilar) for the treatment of relapsed glioblastoma

Biopharmaceutical company Innovent Biologics recently announced that BYVASDA® has been officially approved by China's State Drug Administration (NMPA) for the treatment of reocgenerative glioblastoma (GBM, the most common malignant primary brain tumor), which is byVASDA® in China's third adaptation.
by byVASDA ® approved by China's State Drug Administration (NMPA) for the first time on June 17, 2020.
previously approved ® by BYVASDA include advanced non-small cell lung cancer and metastatic colorectal cancer.
the cancer burden in China has been increasing in recent years.
2018, 4.285 million new cancer diagnoses and 2.865 million cancer deaths in China, according to the World Health Organization's International Agency for Research on Cancer.
, glioblastoma is the most common and invasive brain malignancy, characterized by high morbidity, high recurrence, high mortality and low cure rate.
current treatment options for glioblastoma include surgical excision, radiotherapy and chemotherapy.
survival time is only 12 to 15 months, and there has been no significant change over the past decade.
, glioblastoma patients urgently need more new treatments.
。